Intestinal effects of lipopolysaccharide in rabbit are mediated by cyclooxygenase-2 through p38 mitogen activated protein kinase

European Journal of Pharmacology

Volumn 648, Issue 1-3, 2010, Pages 171-178

  Gonzalo, Sergio ^a   Grasa, Laura ^a   Fagundes, Diego Santos ^a   Arruebo, María Pilar ^a   Plaza, Miguel Ángel ^a   Murillo, María Divina ^a  

^a UNIVERSIDAD DE ZARAGOZA   (Spain)

Author keywords

COX 2; Free radical; Gastrointestinal motility; Lipopolysaccharide; P38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; POTASSIUM CHLORIDE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; GASTROINTESTINAL MOTILITY; INTESTINE CONTRACTION; INTRACELLULAR SIGNALING; LIPID OXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECTUM TEMPERATURE; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 77957749746     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.041     Document Type: Article

References (53)

1. Bradham C., McClay D.R. p38 MAPK in development and cancer. Cell Cycle 2006, 5:824-828.
2. Callahan L.A., Nethery D., Stofan D., DiMarco A., Supinski G. Free radical-induced contractile protein dysfunction in endotoxin-induced sepsis. Am. J. Respir. Cell Mol. Biol. 2001, 24:210-217.
3. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364:229-233.
4. De Filippis D., Iuvone T., Esposito G., Steardo L., Arnold G.H., Paul A.P., De Man J.G., De Winter B.Y. Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J. Pineal Res. 2008, 44:45-51.
5. De Stefano D., Maiuri M.C., Simeon V., Grassia G., Soscia A., Cinelli M.P., Carnuccio R. Lycopene, quercetin and tyrosol prevent macrophage activation induced by gliadin and IFN-gamma. Eur. J. Pharmacol. 2007, 566:192-199.
6. de Winter B.Y., van Nassauw L., de Man J.G., de Jonge F., Bredenoord A.J., Seerden T.C., Herman A.G., Timmermans J.P., Pelckmans P.A. Role of oxidative stress in the pathogenesis of septic ileus in mice. Neurogastroenterol. Motil. 2005, 17:251-261.
7. Ding H., Hashem M., Triggle C. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur. J. Pharmacol. 2007, 561:121-128.
8. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., Lipsky P.E. Cyclooxygenase in biology and disease. Faseb J. 1998, 12:1063-1073.
9. Eberhart C.E., Dubois R.N. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995, 109:285-301.
10. Eckert R.E., Neuder L.E., Bell J.L., Trujillo J.C., Jones S.L. The role of p38 mitogen-activated kinase (MAPK) in the mechanism regulating cyclooxygenase gene expression in equine leukocytes. Vet. Immunol. Immunopathol. 2007, 118:294-303.
11. Ejima K., Layne M.D., Carvajal I.M., Kritek P.A., Baron R.M., Chen Y.H., Vom Saal J., Levy B.D., Yet S.F., Perrella M.A. Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death. Faseb J. 2003, 17:1325-1327.
12. Eskandari M.K., Kalff J.C., Billiar T.R., Lee K.K., Bauer A.J. LPS-induced muscularis macrophage nitric oxide suppresses rat jejunal circular muscle activity. Am. J. Physiol. 1999, 277:G478-G486.
13. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth. Enzymol. 1990, 186:407-421.
14. Fagundes D.S., Gonzalo S., Arruebo M.P., Plaza M.A., Murillo M.D. Melatonin and Trolox ameliorate duodenal LPS-induced disturbances and oxidative stress. Dig. Liver Dis. 2010, 42:40-44.
15. Fornai M., Antonioli L., Colucci R., Bernardini N., Ghisu N., Tuccori M., De Giorgio R., Del Tacca M., Blandizzi C. Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. Pharmacol. Ther. 2010, 125:62-78.
16. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
17. Gan H.T., Pasricha P.J., Chen J.D. Blockade of p38 mitogen-activated protein kinase pathway ameliorates delayed intestinal transit in burned rats. Am. J. Surg. 2007, 193:530-537.
18. Garcia-Mediavilla V., Crespo I., Collado P.S., Esteller A., Sanchez-Campos S., Tunon M.J., Gonzalez-Gallego J. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur. J. Pharmacol. 2007, 557:221-229.
19. Gierse J.K., Hauser S.D., Creely D.P., Koboldt C., Rangwala S.H., Isakson P.C., Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 1995, 305(Pt 2):479-484.
20. Gierse J., Nickols M., Leahy K., Warner J., Zhang Y., Cortes-Burgos L., Carter J., Seibert K., Masferrer J. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur. J. Pharmacol. 2008, 588:93-98.
21. Giralt M., Gasull T., Blanquez A., Hidalgo J. Effect of endotoxin on rat serum, lung and liver lipid peroxidation and on tissue metallothionein levels. Rev. Esp. Fisiol. 1993, 49:73-78.
22. Gonzalo S., Grasa L., Arruebo M.P., Plaza M.A., Murillo M.D. Inhibition of p38 MAPK improves intestinal disturbances and oxidative stress induced in a rabbit endotoxemia model. Neurogastroenterol. Motil. 2010, 22(564-572):e123.
23. Goode H.F., Webster N.R. Free radicals and antioxidants in sepsis. Crit. Care Med. 1993, 21:1770-1776.
24. Grasa L., Arruebo M.P., Plaza M.A., Murillo M.D. PGE(2) receptors and their intracellular mechanisms in rabbit small intestine. Prostaglandins Other Lipid Mediat. 2006, 79:206-217.
25. Grasa L., Arruebo M.P., Plaza M.A., Murillo M.D. A downregulation of nNOS is associated to dysmotility evoked by lipopolysaccharide in rabbit duodenum. J. Physiol. Pharmacol. 2008, 59:511-524.
26. Guerrero-Lindner E., Castro M., Muñoz J.M., Arruebo M.P., Murillo M.D., Bueno L., Plaza M.A. Central tumour necrosis factor-alpha mediates the early gastrointestinal motor disturbances induced by lipopolysaccharide in sheep. Neurogastroenterol. Motil. 2003, 15:307-316.
27. Jin S.H., Kim T.I., Yang K.M., Kim W.H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur. J. Pharmacol. 2007, 558:14-20.
28. Jin F., Wu Q., Lu Y.F., Gong Q.H., Shi J.S. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 2008, 600:78-82.
29. Kim J.Y., Park S.J., Yun K.J., Cho Y.W., Park H.J., Lee K.T. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur. J. Pharmacol. 2008, 584:175-184.
30. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
31. Lavicky J., Raskova H. Different stressors and blood lipid peroxidation. Arzneimittelforschung 1991, 41:793-796.
32. Levine R.L., Williams J.A., Stadtman E.R., Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Meth. Enzymol. 1994, 233:346-357.
33. Lu Y., Wang X., Cederbaum A.I. Lipopolysaccharide-induced liver injury in rats treated with the CYP2E1 inducer pyrazole. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G308-G319.
34. McCubrey J.A., Lahair M.M., Franklin R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8:1775-1789.
35. Menezes G.B., Rezende R.M., Pereira-Silva P.E., Klein A., Cara D.C., Francischi J.N. Differential involvement of cyclooxygenase isoforms in neutrophil migration in vivo and in vitro. Eur. J. Pharmacol. 2008, 598:118-122.
36. Natanson C., Hoffman W.D., Suffredini A.F., Eichacker P.Q., Danner R.L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 1994, 120:771-783.
37. Nowak D., Pietras T., Antczak A., Krol M., Piasecka G. Effect of bacterial lipopolysaccharide on the content of lipid peroxidation products in lungs and other organs of mice. Antonie Leeuwenhoek 1993, 63:77-83.
38. Ono K., Han J. The p38 signal transduction pathway: activation and function. Cell. Signal. 2000, 12:1-13.
39. Parrillo J.E. Pathogenetic mechanisms of septic shock. N Engl J. Med. 1993, 328:1471-1477.
40. Patel N.S., Cuzzocrea S., Collino M., Chaterjee P.K., Mazzon E., Britti D., Yaqoob M.M., Thiemermann C. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur. J. Pharmacol. 2007, 562:148-154.
41. Plaza M.A., Fioramonti J., Bueno L. Role of central interleukin-1 beta in gastrointestinal motor disturbances induced by lipopolysaccharide in sheep. Dig. Dis. Sci. 1997, 42:242-250.
42. Pons L., Droy-Lefaix M.T., Braquet P., Bueno L. Role of free radicals and platelet-activating factor in the genesis of intestinal motor disturbances induced by Escherichia coli endotoxins in rats. Gastroenterology 1991, 100:946-953.
43. Rebollar E., Arruebo M.P., Plaza M.A., Murillo M.D. Effect of lipopolysaccharide on rabbit small intestine muscle contractility in vitro: role of prostaglandins. Neurogastroenterol. Motil. 2002, 14:633-642.
44. Rebollar E., Guerrero-Lindner E., Arruebo M.P., Plaza M.A., Murillo M.D. Role of prostaglandins in lipopolysaccharide effects on K+-induced contractions in rabbit small intestine. Acta Physiol. Scand. 2003, 179:299-307.
45. Riad A., Unger D., Du J., Westermann D., Mohr Z., Sobirey M., Dorenkamp M., Schultheiss H.P., Tschope C. Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. Eur. J. Pharmacol. 2007, 554:40-45.
46. Rowland S.E., Clark P., Gordon R., Mullen A.K., Guay J., Dufresne L., Brideau C., Cote B., Ducharme Y., Mancini J., Chan C.C., Audoly L., Xu D. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species. Eur. J. Pharmacol. 2007, 560:216-224.
47. Shifflett D.E., Jones S.L., Moeser A.J., Blikslager A.T. Mitogen-activated protein kinases regulate COX-2 and mucosal recovery in ischemic-injured porcine ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G906-G913.
48. Supinski G.S., Callahan L.A. Polyethylene glycol-superoxide dismutase prevents endotoxin-induced cardiac dysfunction. Am. J. Respir. Crit. Care Med. 2006, 173:1240-1247.
49. van der Vliet A., Bast A. Role of reactive oxygen species in intestinal diseases. Free Radic. Biol. Med. 1992, 12:499-513.
50. Victor V.M., Rocha M., De la Fuente M. Immune cells: free radicals and antioxidants in sepsis. Int. Immunopharmacol. 2004, 4:327-347.
51. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 2002, 168:5342-5351.
52. Young P.R., McLaughlin M.M., Kumar S., Kassis S., Doyle M.L., McNulty D., Gallagher T.F., Fisher S., McDonnell P.C., Carr S.A., Huddleston M.J., Seibel G., Porter T.G., Livi G.P., Adams J.L., Lee J.C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 1997, 272:12116-12121.
53. Zhou H.Y., Shin E.M., Guo L.Y., Youn U.J., Bae K., Kang S.S., Zou L.B., Kim Y.S. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur. J. Pharmacol. 2008, 586:340-349.